Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2022002100 - NOVEL BENZIMIDAZOLE COMPOUND

Publication Number WO/2022/002100
Publication Date 06.01.2022
International Application No. PCT/CN2021/103366
International Filing Date 30.06.2021
IPC
C07D 401/12 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 401/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 471/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
10Spiro-condensed systems
A61K 31/496 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/4545 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4545containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/5377 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
Applicants
  • 微境生物医药科技(上海)有限公司 WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD. [CN]/[CN]
Inventors
  • 谢雨礼 XIE, Yuli
  • 吴应鸣 WU, Yingming
  • 钱立晖 QIAN, Lihui
  • 樊后兴 FAN, Houxing
Agents
  • 上海弼兴律师事务所 SHANGHAI BESHINING LAW OFFICE
Priority Data
202010629495.X01.07.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) NOVEL BENZIMIDAZOLE COMPOUND
(FR) NOUVEAU COMPOSÉ DE BENZIMIDAZOLE
(ZH) 新型苯并咪唑化合物
Abstract
(EN) The present invention relates to the compound shown in general formula (1), a preparation method therefor, and a use of the compound shown in general formula (1) and isomers, crystal forms, pharmaceutically acceptable salts, hydrates, or solvates thereof as an EGFR inhibitor in the preparation of drugs against EGFR-related diseases such as tumours.
(FR) La présente invention concerne le composé représenté dans la formule générale (1), un procédé de préparation associé, et une utilisation du composé représenté dans la formule générale (1) et des isomères, des formes cristallines, des sels, des hydrates ou des solvates pharmaceutiquement acceptables de ceux-ci en tant qu'inhibiteur d'EGFR dans la préparation de médicaments contre des maladies associées à EGFR telles que des tumeurs.
(ZH) 本发明涉及一种通式(1)所示的化合物及其制备方法,及通式(1)化合物及其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物作为EGFR抑制剂在抗肿瘤等EGFR相关疾病的药物制备中的用途。
Latest bibliographic data on file with the International Bureau